CA2780144A1 - Use of an extract derived from atcc #pta-5863 as an anti-inflammatory and anti-viral agent - Google Patents

Use of an extract derived from atcc #pta-5863 as an anti-inflammatory and anti-viral agent Download PDF

Info

Publication number
CA2780144A1
CA2780144A1 CA2780144A CA2780144A CA2780144A1 CA 2780144 A1 CA2780144 A1 CA 2780144A1 CA 2780144 A CA2780144 A CA 2780144A CA 2780144 A CA2780144 A CA 2780144A CA 2780144 A1 CA2780144 A1 CA 2780144A1
Authority
CA
Canada
Prior art keywords
phyto
percolate
cytokines
approximately
affecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2780144A
Other languages
English (en)
French (fr)
Inventor
Tiffany Thomas
Fazlul Sarkar
Dennis Callewaert
Andrew Dahl
Enrique Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zivo Bioscience Inc
Original Assignee
Health Enhancement Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Enhancement Products Inc filed Critical Health Enhancement Products Inc
Publication of CA2780144A1 publication Critical patent/CA2780144A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2780144A 2009-11-16 2010-11-16 Use of an extract derived from atcc #pta-5863 as an anti-inflammatory and anti-viral agent Abandoned CA2780144A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26163909P 2009-11-16 2009-11-16
US61/261,639 2009-11-16
PCT/US2010/056862 WO2011060427A2 (en) 2009-11-16 2010-11-16 Composition and methods for affecting cytokines and nf-kb

Publications (1)

Publication Number Publication Date
CA2780144A1 true CA2780144A1 (en) 2011-05-19

Family

ID=43992472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2780144A Abandoned CA2780144A1 (en) 2009-11-16 2010-11-16 Use of an extract derived from atcc #pta-5863 as an anti-inflammatory and anti-viral agent

Country Status (6)

Country Link
US (1) US20110117122A1 (enExample)
EP (1) EP2501390A4 (enExample)
JP (1) JP2013510905A (enExample)
BR (1) BR112012011678A2 (enExample)
CA (1) CA2780144A1 (enExample)
WO (1) WO2011060427A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
CA2827401A1 (en) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents and mechanisms for treating hypercholesterolemia
WO2014201372A1 (en) 2013-06-13 2014-12-18 Health Enhancement Products, Inc. Compounds and methods for affecting cytokines
ES2972377T3 (es) 2015-02-16 2024-06-12 Zivo Bioscience Inc Composiciones antinflamatorias e inmunomoduladoras que comprenden Klebsormidium y usos de las mismas
US11806375B2 (en) 2016-02-16 2023-11-07 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9479A (en) * 1852-12-21 Improvement in rakes to grain-harvesters
US10480A (en) * 1854-01-31 Improvement in electro-magnettc engines
US15587A (en) * 1856-08-19 Aepabattts for boeing artesian wells
JPS6219528A (ja) * 1985-07-16 1987-01-28 Kurorera Kogyo Kk 制癌剤
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
WO2001013956A2 (en) * 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
AU7551100A (en) * 1999-09-27 2001-04-30 Algal Ltd. Vegetarian foodstuff
EP1307213B1 (en) * 2000-08-10 2004-04-28 Ocean Nutrition Canada Ltd. Chlorella preparations exhibiting immunomodulating properties
US20020119164A1 (en) * 2000-08-18 2002-08-29 Shoji Uchiyama Use of agaricus blazei murill to prevent or treat skin and other disorders
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
EP1629090B1 (en) * 2002-11-06 2014-03-05 iBio, Inc. Expression of foreign sequences in plants using trans-activation system
US20130251698A1 (en) * 2010-10-04 2013-09-26 Health Enhancement Products, Inc. Composition and method for affecting cytokines and nf-kb
WO2005112987A2 (en) * 2004-04-23 2005-12-01 Health Enhancement Products, Inc. Method of preparation and use of fibrinolytic enzymes in the treatment of disease
US7807622B2 (en) 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
CA2625818A1 (en) * 2005-04-20 2006-10-26 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
EP1954800A4 (en) * 2005-12-02 2010-03-03 Health Enhancement Products In COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE

Also Published As

Publication number Publication date
EP2501390A4 (en) 2014-07-02
JP2013510905A (ja) 2013-03-28
US20110117122A1 (en) 2011-05-19
EP2501390A2 (en) 2012-09-26
WO2011060427A9 (en) 2011-09-15
BR112012011678A2 (pt) 2018-04-17
WO2011060427A2 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
US10765732B2 (en) Compounds and methods for affecting cytokines
Chinn et al. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis
Escoll et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients
Lang et al. Allicin inhibits spontaneous and TNF-α induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells
Jules et al. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis
Taşlı Usage of celery root exosome as an immune suppressant; Lipidomic characterization of apium graveolens originated exosomes and its suppressive effect on PMA/ionomycin mediated CD4+ T lymphocyte activation
CN110870859A (zh) 益生菌代谢物用于延缓衰老迹象
Hu et al. Lycium barbarum polysaccharides attenuate cardiovascular oxidative stress injury by enhancing the Keap1/Nrf2 signaling pathway in exhaustive exercise rats
US20110117122A1 (en) COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-kB
US20130251698A1 (en) Composition and method for affecting cytokines and nf-kb
Baek et al. Parabiotic immunomodulatory activity of yeast cell wall polysaccharides from Saccharomyces cerevisiae and S. boulardii
US10166270B2 (en) Composition and method for affecting cytokines and NF-κB
Xu et al. Functional loss of inactive rhomboid-like protein 2 mitigates obesity by suppressing pro-inflammatory macrophage activation-triggered adipose inflammation
Hutchinson et al. Suppression of granulopoietic progenitor cell proliferation by metabolites of the branched-chain amino acids
Zhao et al. Arctigenin protects mice from thioglycollate‐induced acute peritonitis
Wu et al. Comparison of different processed products of Allium tuberosum Rottler for the treatment of mice asthenozoospermia
EP3148574A1 (en) Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus
DE3421731A1 (de) Humaner-tumor-nekrose-faktor
CN101954071B (zh) 乌司他丁作为制备治疗系统性红斑狼疮药物的用途及其药物组合物
Meijer et al. Membrane and transformation characteristics of lymphocytes isolated from the synovial membrane and paired peripheral blood of patients with rheumatoid arthritis
Ugwudike et al. Python fat: effect on collagen levels of human keloid tissue.
Song et al. Methanolic extracts of Capparis ecuadorica iltis inhibit the inflammatory response in lipopolysaccharide-stimulated RAW 264.7 macrophage cells.
de Gomes et al. Dietary hydrogenated vegetable fat exacerbates the activation of kynurenine pathway caused by peripheral lipopolysaccharide immune challenge in aged mice
Spector et al. Proliferation of macrophages in inflammation
Nurudhin et al. Snail mucus suppresses anti dsDNA antibodies in lupus mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151116

FZDE Discontinued

Effective date: 20180928